Skip to Main Content


Skip Nav Destination

Nominations Now Open for ASH Members to Become Effective Advocates

The 11th annual Advocacy Leadership Institute, coming this October, can help ASH members become effective advocates for their patients and their profession. Read More

Issue Cover
Current Issue
Volume 20,
Issue 3,
May-June 2023

Featured Content

Hematologic Malignancies and the Food and Drug Administration’s Accelerated Approval Program

How is the U.S. Food and Drug Administration's Accelerated Approval program doing when it comes to introducing promising agents to patients with hematologic malignancies?

Why Are There So Few Drugs to Treat Sickle Cell Disease?

Dr. David Rees looks at what’s on the horizon in terms of treatment options for individuals with SCD.

In Which Trial Do I Belong? The PedAL APAL2020SC and EuPAL 2021 Registry Sorting Hats for Relapsed/Refractory Pediatric Acute Leukemias

Drs. Andrew Hughes and Sarah Tasian share their summary and thoughts about a clinical trial with implications for the treatment of pediatric acute leukemias

Close Modal

or Create an Account

Close Modal
Close Modal